Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia: The pilot randomised controlled NOH-PE trial

Thrombosis and Haemostasis

Volumn 106, Issue 6, 2011, Pages 1053-1061

  Gris, Jean Christophe ^a,b,c   Chauleur, Céline ^a,d   Molinari, Nicolas ^b   Marès, Pierre ^b   Fabbro Peray, Pascale ^b   Quéré, Isabelle ^e   Lefrant, Jean Yves ^b   Haddad, Bassam ^f   Dauzat, Michel ^b  

^a UNIV MONTPELLIER   (France)

^b NÎMES UNIVERSITY HOSPITAL   (France)

^c Faculty of Biological and Pharmaceutical Sciences   (France)

^d UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^e MONTPELLIER UNIVERSITY HOSPITAL   (France)

^f UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

Lowmolecular weight heparin; Placental vascular complications; Pre eclampsia; Pregnancy; Randomised controlled trial

Indexed keywords

ACETYLSALICYLIC ACID; ENOXAPARIN;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; INJECTION SITE CONTUSION; NONHUMAN; PREECLAMPSIA; PREGNANCY OUTCOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT DURATION; TREATMENT RESPONSE;

ANTICOAGULANTS; ASPIRIN; COHORT STUDIES; DISEASE PROGRESSION; ENOXAPARIN; FEMALE; FOLLOW-UP STUDIES; GRAVIDITY; HUMANS; PILOT PROJECTS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; TREATMENT OUTCOME;

EID: 82555195546     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-05-0340     Document Type: Article

References (21)

1. Van Rijn BB, Hoeks LB, Bots ML, et al. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol 2006; 195: 723-728.
2. Dildy III GA, Belfort MA, Smulian JC. Preeclampsia recurrence and prevention. Semin Perinatol 2007; 31: 135-141.
3. McDonald SD, Best C, Lam K. The recurrence risk of severe de novo pre-eclampsia in singleton pregnancies: a population-based cohort. Br J Obstet Gynecol 2009; 116: 1578-1584.
4. Hernandez-Diaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in first and subsequent pregnancies: prospective cohort study. Br Med J 2009; 338: b2255.
5. Chang JJ, Muglia LJ, Macones GA. Association of early-onset pre-eclampsia in first pregnancy with normotensive second pregnancy outcomes: a populationbased study. Br J Obstet Gynecol 2010; 117: 946-953.
6. Ananth CV, Peltier MR, Chavez MR, et al. Recurrence of ischemic placental disease. Obstet Gynecol 2007; 110: 128-133.
7. Duley L, Henderson-Smart DJ, Meher S, et al. Antiplatelet agents for preventing preeclampsia and its complications. Cochrane Database Syst Rev 2007; 2: CD004659.
8. Rey E, Garneau P, David M, et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 7: 58-64.
9. Gris JC, Chauleur C, Faillie JL, et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruption placentae. The pilot randomised controlled NOH-AP trial. Thromb Haemost 2010; 104: 771-779.
10. Lissalde-Lavigne G, Fabbro-Peray P, Cochery-Nouvellon E, et al. Factor V Leiden and prothrombin G20210A polymorphisms as risk factors for miscarriage during a first intended pregnancy: the matched case-control 'NOHA first' study. J Thromb Haemost 2005; 3: 2178-2184.
11. Cochery-Nouvellon E, Mercier E, Lissalde-Lavigne G, et al. Homozygosity for the C46T polymorphism of the F12 gene is a risk factor for venous thrombosis during the first pregnancy. J Thromb Haemost 2007; 5: 700-707.
12. Schulman S, Kearon C, on behalf of the subcommittee on control of anticoagulation of the Scientific and Standardization Committee of the International So- ciety on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Scientific and Standardization Committee Communication. J Thromb Haemost 2005; 3: 692-694.
13. Wisser J, Dirschedl P, Krone S. Estimation of gestational age by transvaginal sonographic measurement of greatest embryonic length in dated human embryos. Ultrasound Obstet Gynecol 1994; 4: 457-462.
14. Salomon LJ, Duyme M, Crequat J, et al. French fetal biometry: reference equations and comparison with other charts. Ultrasound Obstet Gynecol 2006; 28: 193-198.
15. Kulkarni A, Chavan-Gautam P, Mehendale S, et al. Global DNA methylation patterns in placenta and its association with maternal hypertension in pre-eclampsia. DNA Cell Biol 2011; 30: 79-84.
16. Chiaffarino F, Ascone GB, Bortulus R, et al. Effects of folic acid supplementation on pregnancy outcomes: a review of randomized clinical trials. Minerva Ginecol 2010; 62: 293-301.
17. Mello G, Parretti E, Fatini C, et al. Low-molecular weight heparin lowers the recurence rate of preclampsia and restores the physiological vascular changes in angiotensin- converting enzyme DD women. Hypertension 2005; 45: 86-91.
18. Smith GC, Crossley JA, Aitken DA, et al. Circulating angiogenic factors in early pregnancy and risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol 2007; 109: 1316-1324.
19. Hossain N, Schatz F, Paidas MJ. Heparin and maternal fetal interface: why should it work to prevent pregnancy complications? Thromb Res 2009; 124: 653-655.
20. Fluhr H, Sprattle J, Ehrhardt J, et al. Heparin and low-molecular-weight heparins modulate the decidualization of human endometrial stromal cells. Fertil Steril 2010; 93: 2581-2587.
21. Yagel S. Angiogenesis in gestational vascular complications. Thromb Res 2011; 127 (Suppl 3): S64-66.